Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Post-menopausal Vasomotor Symptoms
- Main trialPhase 1/2
- “In this clinical research study, subjects will be given the study drug, ACER-801 (osanetant) or placebo (looks like the study drug but contains no active ingredients). The study drug works on a receptor in the brain and the intended purpose is for the study treatment of moderate to severe Vasomotor Symptoms (VMS) also referred to as hot flashes or flushes associated with menopause. Hot flashes are a change in your temperature that occurs due to changes in your hormones.”In the company’s words, NCT05325775 on ClinicalTrials.gov
- Other names
- osanetant
Other drugs for Post-menopausal Vasomotor Symptoms
- FezolinetantAstellas · Phase 3
- ElinzanetantBayer · Phase 3
- AsimadolineTioga Pharmaceuticals · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Completed | 4 Mar 2023 | Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026